Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 26, 2026
Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2B.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 19, 2025
PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial.
Journal: Nature communications
Published: July 18, 2024
Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction.
Journal: The oncologist
Published: June 28, 2024
An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study.
Journal: Gastroenterology
Published: May 01, 2022
Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study.
Journal: Frontiers in oncology
Published: November 05, 2021
A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment.
Journal: Cancer chemotherapy and pharmacology
Published: January 29, 2021
A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.
Journal: Cancer chemotherapy and pharmacology
Published: August 17, 2020
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer.
Journal: Breast cancer research and treatment
Published: February 05, 2020
Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors.
Journal: Cancer chemotherapy and pharmacology
Published: September 05, 2019
Analysis of recurrently protected genomic regions in cell-free DNA found in urine.
Journal: Science translational medicine
Published: August 29, 2019
Last Updated: 09/26/2026